Houston Methodist has been recognized in two different awards programs. Courtesy of Methodist Hospital/Facebook

Houston Methodist has a couple new feathers in its cap. The hospital system was recognized with two different awards recently.

Houston Methodist was the only hospital system to have four hospitals receive a 2019 Vizient Bernard A. Birnbaum, M.D., Quality Leadership Award, a recognition that praises hospitals for demonstrating quality and care. The Vizient Quality and Accountability Study has been conducted every year since 2005.

Houston Methodist Hospital was recognized in the in the comprehensive academic medical center category, Houston Methodist Sugar Land received an award in the specialized complex care medical center category, and both Houston Methodist Willowbrook and Houston Methodist The Woodlands were selected for the complex medical center category.

"Having four of our hospitals on this list is extraordinary. Receiving such national recognition is an honor, but I'm most proud that the reason for these awards is our concerted focus on quality patient care," says Marc L. Boom, president and CEO of Houston Methodist, in a news release.

This year was slightly different from years prior, and 349 participating hospitals were divided into four cohorts for the Vizient Quality and Accountability Ranking. Among some of the assets considered were safety, mortality, clinical effectiveness, efficiency and patient centeredness. The announcement was made last week during the 2019 Vizient Connections Education Summit in Las Vegas.

Meanwhile, the hospital system was also recently recognized for being among the "Most Wired" in the United States. For the 12th consecutive year, Houston Methodist received the 2019 HealthCare's Most Wired recognition from the College of Healthcare Information Management Executives, or CHiME. The award recognizes hospital systems for their innovation, adoption, and optimal use of information technology.

New this year was CHiME's ambulatory facilities recognition, which Houston Methodist received for outstanding technical accomplishments, earning a Certified Level 8 Quality Award.

Innovation has an increased focus at Houston Methodist since premiering its Center for Innovation — a group of leaders charged with finding new technologies for the hospital system for patients, physicians, and staff — under the leadership of Roberta Schwartz. She is the system's executive vice president, chief innovation officer, and chief executive officer of Houston Methodist Hospital.

After 17 years at Houston Methodist, Schwartz says she's seen the evolution of tech and is taking note of where the industry is going.

"I think we're an industry that is transforming itself. We're either going to be disrupted or we're going to do the disruption ourselves," Schwartz tells InnovationMap in a previous article. "There's nobody who knows health care better than we do, so if we're going to transform the industry, I want that transformation to come from the inside."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

European spacecraft developer expands to Houston with U.S. business, new lab

houston hq

European aerospace manufacturer The Exploration Company has established its first U.S. entity and named Space City as its headquarters.

The company announced earlier this month that it has launched TEC Federal to support U.S. government customers and agencies, and to scale The Exploration Company's engineering operations in the country.

Mark Kirasich serves as president of TEC Federal. Kirasich most recently served as the senior director of human spaceflight at Blue Origin after a nearly 40-year career at NASA.

The Exploration Company is developing the reusable Nyx space vehicle. Nyx is designed to take off from any heavy launcher in the world. It will then dock at space stations, retrieve up to 3,000 kilograms of cargo, splash down and return the cargo to Earth. The company aims to make Nyx fully reusable for up to 10 missions, making it a more affordable and sustainable option for aerospace missions.

The Exploration Company completed a successful drop test of the spacecraft in May in the Mojave Desert. The company says Nyx is slated to perform its first flight demonstration in 2028.

In addition to launching the Houston business, The Exploration Company also opened its new Rapid Innovation Lab near Houston's NASA Johnson Space Center on Space Park Drive.

The Exploration Company opened its Rapid Innovation Lab earlier this month. Photo via LinkedIn

The Rapid Innovation Lab features a full-scale mockup of the future Nyx crew capsule as well as ongoing development and testing of the Nyx cargo capsule, according to the company.

The Exploration Company says the new lab will allow its engineers, designers, and operators to prototype and test crew interfaces. It will also support partnerships with NASA personnel and astronauts.

“Houston gives us direct access to the people and expertise that have built and operated human spaceflight systems for decades. We’re excited to invest and expand around that— engineers, operators, and astronauts working together and moving quickly towards building a crew capsule.” Hélène Huby, founder and CEO of The Exploration Company, said in a blog post.

According to The Houston Chronicle, The Exploration Company has about 30 employees in the Houston area.

The company was founded in 2021 by Huby, a French rocket scientist, and has raised more than $350 million in venture capital. It operates out of Germany, France, Luxembourg, Spain and Italy, with offices in the U.S. and the United Arab Emirates. It is also developing a reusable, high-thrust rocket engine known as Storm.

UH lands $4M NIH grant to study early signs of autoimmune disease

NIH funding

The University of Houston recently received a $4 million National Institutes of Health grant to support a 10-year longitudinal study to identify the earliest biological markers of autoimmune disease.

Led by Chandra Mohan, the Hugh Roy and Lillie Cranz Cullen Endowed Professor of Biomedical Engineering, the study aims to examine what causes Systemic Autoimmune Rheumatic Diseases (SARDs) and to identify targets for future treatments. The study will be carried out in collaboration with Dr. Karen Costenbader at Harvard Medical School, Boston.

SARDs include conditions like rheumatoid arthritis, systemic lupus erythematosus, Sjögren’s syndrome and systemic sclerosis—all are considered chronic diseases currently without a cure. Autoimmune diseases affect over 30 million people globally, according to UH.

SARDs occur when the body’s immune system attacks healthy, non-threatening tissues and organs. According to UH, in these diseases, the body often attacks nuclear antigens, creating anti-nuclear autoantibodies, which can be early detection signs for SARDs in more than 50 percent of patients, Mohan says.

Researchers will study blood samples and environmental exposure over the 10 years to better understand anti-nuclear autoantibodies.

“Collectively, these studies will help identify the genetic, environmental and cellular factors that are operative at the two steps of SARD development, namely the emergence of anti-nuclear autoantibodies and disease onset,” Mohan said in a news release. “ More importantly, these studies will highlight functional molecular pathways and mechanisms that may be operative at each step."

Mohan predicts that looking at SARDs’ shared characteristics, rather than each disease individually, could help identify more treatment methods.

“Individual SARDs have been examined in silos without an attempt to discern shared underlying features at the molecular level,” he added in the release. “Current understanding of the initial (and likely shared) origins of SARDs is only rudimentary but urgently needed to develop means for prevention and treatment.”

Earlier this year, UH also received an $11 million NIH grant to conduct a first-of-its-kind study of early language development in children ages 18 to 24 months. Read more here.